WINSTON-SALEM, N.C. — AstraZeneca and Targacept released results of the second of four phase-3 clinical trials that investigated the efficacy and tolerability of a drug that could serve as an adjunct therapy to major depressive disorder patients that had an inadequate response to initial antidepressant therapies.
PARSIPPANY, N.J. — Generic drug maker Watson and biotech manufacturer Amgen will work together to develop biosimilar antibodies for treating cancer, the two companies said.
BURLINGTON, Mass. — The market for drugs to treat ulcerative colitis will increase from 2010's $1.7 billion to $3 billion in 2020, according to a new report by market research firm Decision Resources.
VALLEY FORGE, Pa. — US Bioservices, the specialty pharmacy of AmerisourceBergen, on Monday announced that it had received the Specialty Pharmacy Accreditation from URAC, a Washington-based healthcare accrediting organization that establishes quality standards for the healthcare industry.
WASHINGTON — One-in-eight Americans didn't fill prescriptions last year because they couldn't afford to, but despite difficulties with the economy, that proportion remained level, according to a new study conducted by the Center for Studying Health System Change and funded by the Robert Wood Johnson Foundation.
PITMAN, N.J. — According to an article in the November/December issue of the journal Medical-Surgical Nursing, rates of HIV/AIDS, herpes, syphilis, human papilloma virus and other STDs are climbing steadily across men and women older than 50 years.
SAM MATEO, Calif. — A Food and Drug Administration expert panel will review a drug made by NeurogesX as a potential treatment for pain associated with HIV.
NeurogesX said Thursday that the FDA Anesthetic and Analgesic Drug Products Advisory Committee would meet on Feb. 9, 2012, to review the patch drug Qutenza (capsaicin) as a treatment for pain associated with HIV-associated peripheral neuropathy, or HIV-PN.
The drug currently is approved for treating pain associated with postherpetic neuralgia.
